Does Monoamine Oxidase Inhibitors Maois Interact with Methylprednisolone Acetate Lidocaine Hydrochloride Bupivacai?
Monoamine Oxidase Inhibitors Maois and Methylprednisolone Acetate Lidocaine Hydrochloride Bupivacai have a major drug interaction according to U.S. FDA drug labeling data. Administration of Bupivacaine Hydrochloride and Epinephrine to patients receiving MAOIs may produce severe, prolonged hypertension. Concurrent use should generally be avoided. The mechanism involves vasoconstrictor interaction with catecholamine metabolism. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Monoamine Oxidase Inhibitors Maois and Methylprednisolone Acetate Lidocaine Hydrochloride Bupivacai occurs because vasoconstrictor interaction with catecholamine metabolism. Clinically, this means administration of bupivacaine hydrochloride and epinephrine to patients receiving maois may produce severe, prolonged hypertension. concurrent use should generally be avoided. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Monoamine Oxidase Inhibitors Maois and your doctor is considering prescribing Methylprednisolone Acetate Lidocaine Hydrochloride Bupivacai (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider